CAR-T Therapy for Richter Transformation
July 29, 2025
CAR-T therapy can be effective in certain patients with Richter transformation.
CAR-T therapy can be effective in certain patients with Richter transformation.
CAR-T therapy can provide very long remissions in a subset of patients with relapsed / refractory CLL who responded for at least one year.
Lisocabtagene Maraleucel (liso-cel), a CAR-T therapy, is effective but only in a minority of chronic lymphocytic leukemia (CLL) patients.
CAR-T therapy is a potent cellular immune treatment that genetically trains an individual’s immune system to both recognize and attack cancerous cells.
An experimental CAR-T cell therapy made from healthy donor T cells is being tested in an ongoing phase 1 clinical trial to treat B Cell cancers.
Chimeric Antigen Receptor T-cell (CAR-T) therapy is a potent cellular immune treatment that genetically trains an individual’s immune system (specifically, the T-cells, a type of white blood cell) to both recognize and attack cancerous cells.
Chimeric antigen receptor T-cell (CAR-T) therapy can provide durable remissions in a subset of patients with Richter’s transformation.
Chimeric antigen receptor T-cell (CAR-T) therapy can provide durable remissions in a subset of patients with Richter’s transformation.
This research shows that senescence (biological aging) can occur in CAR-T cells, reducing their ability to kill cancer cells.